Cargando…
Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial
Background: Proton pump inhibitors are effective for functional dyspepsia but ineffective in relieving postprandial distress syndrome. Curcuma longa might be effective for postprandial distress syndrome. The objective of this study was to compare the efficacy of Curcuma longa and simethicone for pos...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809885/ https://www.ncbi.nlm.nih.gov/pubmed/33510892 http://dx.doi.org/10.12688/f1000research.20662.1 |
_version_ | 1783637206462627840 |
---|---|
author | Sawangroj, Nicharat Budkaew, Jiratha Chumworathayi, Bandit |
author_facet | Sawangroj, Nicharat Budkaew, Jiratha Chumworathayi, Bandit |
author_sort | Sawangroj, Nicharat |
collection | PubMed |
description | Background: Proton pump inhibitors are effective for functional dyspepsia but ineffective in relieving postprandial distress syndrome. Curcuma longa might be effective for postprandial distress syndrome. The objective of this study was to compare the efficacy of Curcuma longa and simethicone for postprandial distress syndrome in an open-label randomized-controlled trial. Methods: This trial was conducted between July 2018 and February 2019. In total, 78 patients were randomly assigned to receive 4 weeks of treatment with 750 or 1,500 mg oral Curcuma longa per day or 240 mg simethicone per day. The patients assessed their symptoms using the dyspepsia Global Overall Symptom scale at baseline, week 2, and week 4. After stopping medication for 2 weeks, the patients assessed recurrent symptoms and day of recurrence by themselves at the end of week 6. Results: In total, 78 patients underwent randomization (27 in 750 mg Curcuma longa, 26 in 1500 mg Curcuma longa, and 25 in simethicone groups). After 2 weeks, there were no significant differences in all mean changes of symptoms scores (95%CI) of postprandial distress syndrome [-4.1 (-4.5, -2.6) vs -4.3 (-5.2, -3.3) vs -4.2 (-4.8, -3.5), P=0.954]. Over a period of 4 weeks, the reduction in mean scores was greater among participants receiving simethicone (although not statistically significant) compared with two intervention groups [-4.6 (-5.7, -3.6) vs -5.4 (-6.6, -4.1) vs -6.2 (-7.2, -5.2), P=0.122]. The rate of recurrence was significantly lower in simethicone than the two Curcuma longa groups (42.9 vs 45.5 vs 13.6%, P=0.047). There was no serious adverse event reported in all three groups. Conclusions: Curcuma longa had a similar effect on treatment outcomes to simethicone after 2 and 4 weeks, but the recurrence rate of symptoms was significantly higher without serious adverse events. Registration: Registered with the Thai Clinical Trials Registry on 31 January 2018; TCTR20180131001. |
format | Online Article Text |
id | pubmed-7809885 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-78098852021-01-27 Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial Sawangroj, Nicharat Budkaew, Jiratha Chumworathayi, Bandit F1000Res Research Article Background: Proton pump inhibitors are effective for functional dyspepsia but ineffective in relieving postprandial distress syndrome. Curcuma longa might be effective for postprandial distress syndrome. The objective of this study was to compare the efficacy of Curcuma longa and simethicone for postprandial distress syndrome in an open-label randomized-controlled trial. Methods: This trial was conducted between July 2018 and February 2019. In total, 78 patients were randomly assigned to receive 4 weeks of treatment with 750 or 1,500 mg oral Curcuma longa per day or 240 mg simethicone per day. The patients assessed their symptoms using the dyspepsia Global Overall Symptom scale at baseline, week 2, and week 4. After stopping medication for 2 weeks, the patients assessed recurrent symptoms and day of recurrence by themselves at the end of week 6. Results: In total, 78 patients underwent randomization (27 in 750 mg Curcuma longa, 26 in 1500 mg Curcuma longa, and 25 in simethicone groups). After 2 weeks, there were no significant differences in all mean changes of symptoms scores (95%CI) of postprandial distress syndrome [-4.1 (-4.5, -2.6) vs -4.3 (-5.2, -3.3) vs -4.2 (-4.8, -3.5), P=0.954]. Over a period of 4 weeks, the reduction in mean scores was greater among participants receiving simethicone (although not statistically significant) compared with two intervention groups [-4.6 (-5.7, -3.6) vs -5.4 (-6.6, -4.1) vs -6.2 (-7.2, -5.2), P=0.122]. The rate of recurrence was significantly lower in simethicone than the two Curcuma longa groups (42.9 vs 45.5 vs 13.6%, P=0.047). There was no serious adverse event reported in all three groups. Conclusions: Curcuma longa had a similar effect on treatment outcomes to simethicone after 2 and 4 weeks, but the recurrence rate of symptoms was significantly higher without serious adverse events. Registration: Registered with the Thai Clinical Trials Registry on 31 January 2018; TCTR20180131001. F1000 Research Limited 2019-10-30 /pmc/articles/PMC7809885/ /pubmed/33510892 http://dx.doi.org/10.12688/f1000research.20662.1 Text en Copyright: © 2019 Sawangroj N et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Sawangroj, Nicharat Budkaew, Jiratha Chumworathayi, Bandit Efficacy of Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial |
title | Efficacy of
Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial |
title_full | Efficacy of
Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial |
title_fullStr | Efficacy of
Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial |
title_full_unstemmed | Efficacy of
Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial |
title_short | Efficacy of
Curcuma longa in treatment of postprandial distress syndrome: An open-label randomized-controlled trial |
title_sort | efficacy of
curcuma longa in treatment of postprandial distress syndrome: an open-label randomized-controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809885/ https://www.ncbi.nlm.nih.gov/pubmed/33510892 http://dx.doi.org/10.12688/f1000research.20662.1 |
work_keys_str_mv | AT sawangrojnicharat efficacyofcurcumalongaintreatmentofpostprandialdistresssyndromeanopenlabelrandomizedcontrolledtrial AT budkaewjiratha efficacyofcurcumalongaintreatmentofpostprandialdistresssyndromeanopenlabelrandomizedcontrolledtrial AT chumworathayibandit efficacyofcurcumalongaintreatmentofpostprandialdistresssyndromeanopenlabelrandomizedcontrolledtrial |